Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
NU300 (HibTITER) Booster Co-administered with Prevnar 13 in Toddlers
NCT01732198Phase 2Unknown
- Sponsor
- Nuron Biotech, Inc.
- Start
- Mar 2013
- Primary completion
- Jan 2014
- Modality
- Recombinant Proteins and Enzymes, Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of Haemophilus b conjugate vaccine in Haemophilus influenzae type b infection (Hib) (2 arms), sponsored by Nuron Biotech, Inc. Primary endpoint: Safety and Efficacy at 1 month. Status: unknown.
02
Drugs
Haemophilus b conjugate vaccine
03
Conditions
Haemophilus influenzae type b infection (Hib)
Beyond the preview
Go deeper on NCT01732198.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01732198.